Thomas Jefferson University

Jefferson Digital Commons
Department of Neurosurgery Faculty Papers

Department of Neurosurgery

4-20-2022

Targeted Therapy in the Management of Modern
Craniopharyngiomas
Maikerly Reyes
Mohammad Taghvaei
Siyuan Yu
Anish Sathe
Sarah Collopy

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/neurosurgeryfp
Part of the Neurology Commons, and the Surgery Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurosurgery Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Maikerly Reyes, Mohammad Taghvaei, Siyuan Yu, Anish Sathe, Sarah Collopy, Giyarpuram Prashant,
James J. Evans, and Michael Karsy

Front. Biosci. (Landmark Ed) 2022; 27(4): 136
https://doi.org/10.31083/j.fbl2704136

Review

Targeted Therapy in the Management of Modern Craniopharyngiomas
Maikerly Reyes1,† , Mohammad Taghvaei1,† , Siyuan Yu1,† , Anish Sathe1,† , Sarah Collopy1,† ,
Giyarpuram N. Prashant1,† , James J. Evans1 , Michael Karsy2, *
1 Department

of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
of Neurosurgery, University of Utah, Salt Lake City, UT 84132, USA
*Correspondence: michael.karsy@hsc.utah.edu (Michael Karsy)
† These authors contributed equally.
Academic Editor: Graham Pawelec
Submitted: 29 November 2021 Revised: 26 January 2022 Accepted: 9 February 2022 Published: 20 April 2022

2 Department

Abstract
Background: The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and
endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic markers
implicated in CP, their involvement in tumorigenic pathways, and their impact on CP prognosis and treatment. Methods: We undertook a
focused review of relevant articles, clinical trials, and molecular summaries regarding CP. Results: Genetic and immunological markers
show variable expression in different types of CP. BRAF is implicated in tumorigenesis in papillary CP (pCP), whereas CTNNB1 and
EGFR are often overexpressed in adamantinomatous CP (aCP) and VEGF is overexpressed in aCP and recurrent CP. Targeted treatment
modalities inhibiting these pathways can shrink or halt progression of CP. In addition, EGFR inhibitors may sensitize tumors to radiation
therapy. These drugs show promise in medical management and neoadjuvant therapy for CP. Immunotherapy, including anti-interleukin-6
(IL-6) drugs and interferon treatment, are also effective in managing tumor growth. Ongoing clinical trials in CP are limited but are testing
BRAF/MET inhibitors and IL-6 monoclonal antibodies. Conclusions: Genetic and immunological markers show variable expression in
different subtypes of CP. Several current molecular treatments have shown some success in the management of this disease. Additional
clinical trials and targeted therapies will be important to improve CP patient outcomes.
Keywords: craniopharyngioma; adamantinomatous; papillary; BRAF; beta-catenin; CTNNB1; immunotherapy; molecular biology;
EGFR

1. Introduction
Craniopharyngiomas (CPs) can result in high levels
of morbidity and mortality because of their involvement
of critical neurovascular structures. Available treatment
strategies, including surgery and radiotherapy, have limitations and known complication profiles. Thus, novel therapies are needed to improve long-term outcomes postoperatively. Currently, no medical therapies are widely established to treat CPs, but recent advances in molecular
biology have revealed potential molecular pathways that
could be exploited to develop new therapeutics. Targeted
molecular therapy has the potential to minimize the adverse
outcomes currently associated with medical management
of CPs. Here, we performed a scoping review of known
molecular pathways and markers identified in the pathogenesis of CP and evaluate studies/case reports and current clinical trials evaluating the use of targeted treatments. Search
terms for “targeted treatment”, “craniopharyngioma”, and
repeat searches for key identified genes was performed.

2. Epidemiology and Clinical Features
CPs are benign epithelial tumors that originate from
the sellar region, specifically the craniopharyngeal duct.
They are classified as World Health Organization grade I

lesions [1] and show a bimodal age distribution, with peak
incidence rates observed in children aged 5–14 and adults
aged 50–74 years [2]. These tumors are quite rare, with incidences ranging from 0.17 to 0.2 cases per 100,000 people
in the U.S [3].
CPs may present with focal neurological deficits, ophthalmologic disturbances, endocrinopathies, and evidence
of intracranial hypertension [4,5]. Ophthalmologic disturbances, seen in 62–84% of patients, may manifest as bitemporal hemianopsia due to compression of the optic chiasm
or visual disturbance secondary to intracranial hypertension. Endocrinopathies occur because of damage to the
hypothalamic–pituitary axis and can be present at time of
diagnosis [6]. Endocrinopathies are seen in 52–87% of
patients and include one or more hormonal deficiencies
and panhypopituitarism. Patients may also present with
diabetes insipidus or develop it along the course of treatment. Focal neurological deficits may include seizures,
headaches, nausea, vomiting, and hydrocephalus [7].
Clinical manifestations are heavily dependent on the
anatomic location of the CP, specifically whether the tumor
is in a prechiasmal, retrochiasmal, or intrasellar location [4].
Tumors in prechiasmal locations are more likely to manifest
with visual disturbances and optic atrophy, whereas those in
retrochiasmal locations present with increased intracranial
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pressure and hydrocephalus and intrasellar tumors typically
manifest with headache and endocrinopathies. Diagnosis of
childhood CP is usually made late, often years after the initial symptoms manifest [8]. In children, any combination
of headache, visual deficits, regressed development or reduced growth rate, and/or polydipsia should include CP as
a differential diagnosis.

3. Current Management
Craniopharyngiomas pose a significant challenge in
medical management because of their proximity to neurovascular elements, the hypothalamus, subcortical structures, and the cerebral cortex [9]. An infiltrative and unpredictable growth pattern is often seen, making safe resection difficult. Despite advances in surgical management
and radiation, the morbidity and mortality of patients with
CP remains high, highlighting a need for the development
of novel treatment approaches. CPs have the highest mortality rate of sellar tumors, even after adjusting for other
clinical factors [10]. Overall mortality may be 3–5 times
higher than the baseline population risk [5,11]. Morbidity and mortality for CPs are influenced by tumor location, tumor size, and treatment strategy. Overall survival
in mixed pediatric and adult populations has been reported
to be between 54–96% at 5 years, 40–93% at 10 years, and
66–85% at 20 years, indicating that conventional surgical
care is not sufficient for improved survival [5]. Complications of CP treatment can include visual loss, panhypopituitarism, diabetes insipidus, obesity, cardiovascular disease,
stroke, sleep disturbances, dysfunctional thermoregulation
and thirst, and lower bone density [12].
Current treatment options rely on maximal safe resection; the choice of gross-total resection (GTR) or subtotal resection (STR) depends on the extent of encasement
or invasion of critical neurovascular structures. Regardless of the extent of resection, multidisciplinary treatment
at experienced centers for management of CPs is favored to
improve extent-of-resection and reduce neurological morbidity [13]. Radiotherapy, although beneficial in reducing tumor recurrence, is controversial due to the potential
neurovascular morbidity. Post-operative conventional radiotherapy (CRT) for CP is associated with new pituitary
deficits, including worsening of partial hypopituitarism, observed in 20–60% of irradiated patients studied in the literature, and radiation induced optic neuropathy [14,15]. In
contrast, fractionated stereotactic radiation therapy (FSRT)
and stereotactic radiosurgery (SRS) have lower toxicity
rates and greater safety and efficacy in terms of hypothalamic and visual function. As a result, SRS and FSRT have
largely replaced CRT methods for post-operative treatment
of CP. In addition, optimal timing after tumor resection,
whether immediately after surgery or after tumor progression, is undetermined. In a study of adults with CP undergoing GTR, STR + adjuvant radiotherapy, or STR alone, the
rates of recurrence were similar between GTR and STR +
2

adjuvant radiotherapy [16]. Furthermore, a meta-analysis
of 744 CP patients undergoing GTR vs. STR + adjuvant
radiotherapy showed no difference in overall survival and
progression-free survival between groups [17]. However,
a retrospective review of a pediatric cohort with primary
and recurrent CP showed that patients with upfront GTR
had significantly longer progression-free survival, supporting the notion that GTR offers a better chance of disease
control and cure [18].
On the other hand, several studies have shown that
GTR is associated with a higher risk of neurologic, ophthalmic, and endocrinological deficits. In the pediatric
population GTR has higher morbidity and mortality related to hypothalamic dysfunction including hyperphagia,
hypothalamic obesity, thermal dysregulation, diabetes insipidus, and cognitive deficits [19]. A retrospective, singlecenter analysis of 178 pediatric patients treated between
1960 and 2017 showed that radical resection was associated with higher risks of worsening visual acuity, panhypopituitarism, diabetes insipidus, psychosocial impairment,
and new-onset obesity [20]. Importantly, while conservative management showed a higher risk of multiple recurrences and radiation induced vasculopathy, this was balanced by similar rates of tumor control and a lower risk of
long-term morbidities in comparison to GTR. Another retrospective analysis of 30 pediatric patients found that GTR
resulted in an average loss of 9.8 points of IQ while a combined surgical/radiotherapy group lost an average of only
1.25 points [21]. Long-term adverse effects of radiotherapy include hormone deficiencies, hearing loss, vision loss,
and cognitive worsening [5]. Similarly, a study on the extent of resection and long-term functional outcome in adults
with craniopharyngioma found that conservative management led to equal long term visual, endocrinological, and
hypothalamic outcomes in comparison to GTR [22]. Additionally, the addition of adjuvant radiotherapy with STR led
to better local control of the tumor, and none of the patients
that received this intervention had recurrence for more than
five years in the follow up period.
Overall, studies have shown that radical resection has
similar benefit but an increased risk of deficits compared
with STR + adjuvant radiotherapy, which has resulted in a
practice shift over time to maximize function and quality of
life. These studies remain difficult to compare over time
because of variations in treatments strategies. Nonetheless, the refinement of less invasive surgical approaches has
helped foster a need to better understand CPs and derive
new treatment options.

4. Papillary and Adamantinomatous CPs
CPs can occur as either of two primary histologic
subtypes, namely adamantinomatous (aCP) and papillary
(pCP) (Table 1, Fig. 1). The aCP subtype is more prevalent overall, more common in children and is characterized
by cystic and/or solid components, calcifications, necrotic

Table 1. Differential characteristics between aCP and pCP.
Characteristic
Age
Tumor type
Calcifications and necrosis debris
Histologic hallmarks

Surgical margins
Invasion
Mutation

Adamantinomatous CP

Papillary CP

More common in children
Cystic and/or solid components
Frequent
Peripheral basal cell layer of palisading
epithelium and nodules of wet keratin and
anucleated cells
Frequently irregular
More aggressive
CTNNB1

More common in adults
Solid and/or cystic components
Uncommon
Squamous epithelium creating papillae of
different sizes and lack of a basal cell layer of
palisading cells
Well demarcated
Less aggressive
BRAFV 600E

debris, and fibrous tissue [23]. Surgical margins in aCP
are more frequently irregular, making resection difficult.
Histologic hallmarks include a peripheral basal cell layer
of palisading epithelium, loosely aggregated stellate cells,
and nodules of wet keratin and anucleated cells [23,24].
Wet keratin is highly calcified and grossly appears as white
flecks.
In contrast, pCPs are more common in adults, are usually well demarcated, and do not tend to invade nearby critical structures. Macroscopically, pCPs are solid or mixed
with cystic and solid components. Calcifications are uncommon in pCPs. Histologically, they show growing cells
with squamous epithelium creating papillae of different
sizes and lack a basal cell layer of palisading cells.
Furthermore, histologic subtyping to determine risk
factors for CP recurrence has yielded conflicting evidence.
In some studies, pCPs have shown higher 5-year survival
rates, less aggressive disease progression, and less risk of
recurrence in comparison to aCPs [25]. However, other
studies have not found significant differences [6,26]. Although aCPs are more likely to be invasive and make GTR
more challenging, no differences in recurrence have been
found between aCPs and pCPs independent of resection status [25]. GTR seems to be the most important factor influencing risk of recurrence.
Not only are their histological features distinct, but
aCPs and pCPs demonstrate differing gene and methylation patterns [27]. DNA methylation profiling after analysis of the most variably methylated CpG sites has shown
that aCPs and pCPs are characterized by two unique methylation clusters [27]. Therefore, histologic subtypes also
differ on an epigenetic and transcriptional level. Furthermore, whole-exome sequencing has revealed that aCPs and
pCPs consist of mutations that are mutually exclusive and
clonal, specifically catenin beta 1 (CTNNB1) and B-Raf
(BRAFV 600E ) mutations, respectively [28]. CTNNB1 was
the most commonly mutated gene in aCPs, present in 11
of the 12 tumor specimens, and exclusive to exon 3. In
contrast, pCPs had mutations in the BRAFV 600E gene and
no mutations for CTNNB1. Similarly, mutational analysis
of a larger number of CP tumor samples showed activating mutations and deletions in exon 3 of the CTNNB1 gene

exclusive to aCP tumors [27]. In contrast, BRAF mutations
were only found in pCP tumors, with subsequent Sanger sequencing confirming the BRAFV 600E mutation. It is likely
that these and other mutational pathways account for the
clinical variation seen in CP subtypes and play a role in patient outcomes.

5. BRAF mutations in pCPs
BRAF mutations are implicated in the tumorigenesis of pCPs. Whole-exome sequencing, next-generation
panel sequencing, pyrosequencing, and Sanger sequencing revealed the prevalence of BRAF mutations in pCPs in
81–100% of tumors [3,28–30]. The BRAFV 600E mutation
leads to glutamic acid in place of valine and uncontrolled
activation of this serine threonine kinase that normally
regulates the mitogen-activated protein kinase/extracellular
signal–related kinase (MAPK/ERK) signaling pathway.
The MAP/ERK pathway is well known for its role in
cell proliferation and differentiation. The existence of a
BRAFV 600E mutation–specific antibody (VE1) can be diagnostic, especially in cases where diagnosis of pCPs is
challenging, but its specificity is still unclear and the use
of sequencing is often required.
Recent studies have shown the possibility of targeted
therapy with BRAFV 600E inhibitors, which have demonstrated success in treatment of other malignancies harboring this mutation [29,31–40]. Some recent studies have also
shown that magnetic resonance imaging features have been
used to successfully predict the presence of BRAFV 600E
mutations in patients with CPs with high sensitivity and
specificity [41]. These features include suprasellar tumor
location, spherical shape, solid component predominance,
homogeneous enhancement, and thickened pituitary stalk.
Improved preoperative determination of genetic drivers in
CP may aid in designing neoadjuvant targeted therapy. Preoperative genetic status may alter surgical decision-making,
which can potentially better justify an STR in a situation
where good postoperative adjuvant treatments are available.
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Fig. 1. Overview of symptoms and clinical changes from craniopharyngioma.

6. CTNNB1 Mutations and Pathogenesis in
aCPs
Disruption of the catenin β-1 (CTNNB1) and the corresponding Wnt pathway are implicated in the tumorigenesis
of aCPs (Fig. 2). β-catenin is found either in the cell membrane or the cytoplasm, where it is to be degraded by proteasomes [24]. aCPs show upregulation of the β-catenin/Wnt
(LEF1 and AXIN2) and sonic hedgehog (SHH) signaling
(GLI2, PTCH1, and SHH) pathways in comparison with
pCPs. β-catenin is regulated by a destruction complex
consisting of tumor suppressor adenomatous polyposis coli
(APC), scaffolding proteins Axin1/Axin2, and phosphokinases GSK3B and CK1. Once bound to the complex, βcatenin is phosphorylated on its N-terminal region encoded
by exon 3. Mutations in exon 3 in the CTNNB1 gene lead to
constitutive β-catenin activity by inhibiting its phosphorylation and degradation [42]. The Wnt pathway becomes activated upon Wnt ligand binding to receptors, which leads
to inhibited degradation of β-catenin and GSK3B, allowing relocation of the ligand-binding complex to the nucleus
where β-catenin leads to activation of lymphoid enhancer
4

factor and T-cell factor transcription factors. CTNNB1 mutations can impact a wide array of pathways involved in cell
proliferation, differentiation, and cell migration [42].
Genetically engineered mouse models expressing
oncogenic β-catenin have shown that overactivation of the
Wnt pathway is sufficient to lead to formation of tumors that
parallel human aCPs and consist of cell clusters accumulating β-catenin [3]. However, it is vital to note that mouse
aCPs can lack wet keratin and calcifications and thus do not
completely parallel human aCPs. Although mouse models,
primary cell cultures, and xenografts are clinically useful
in the study of aCPs, they do not recapitulate all the characteristics of human aCPs, highlighting a need for more comparable human models [3]. A xenotransplant mouse model
has been proposed to better study potential novel therapies
[43].
The β-catenin/Wnt pathway has proven to be an essential potential target of novel therapies for CP. To our knowledge, there are no ongoing clinical trials targeting the βcatenin/Wnt pathway in CP tumors, although Wnt pathway
inhibition is currently being investigated for non–central

Fig. 2. Signaling pathway and targeting of adamantinomatous craniopharyngioma. Upregulation of the β-catenin signaling pathway
is governed by mutant β-catenin, which resists ubiquitin-mediated proteolysis. Upregulation of sonic hedgehog (SHH) signaling is seen
along with the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signaling pathways. Only
targeted therapy of EGFR, VEGF, and inflammatory cytokines has been described with adamantinomatous craniopharyngioma. APC,
adenomatous polyposis coli; CKIα, casein kinase 1 alpha; GLI1, glioma-associated oncogene; Hh, sonic hedgehog; LRP, low-density
lipoprotein receptor-related protein; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinases; PTCH, patched; SMO,
smoothened; SUFU, suppressor of fused homolog; TCF/LEF, T-cell factor/lymphoid enhancer-binding factor; VEGF, vascular endothelial
growth factor.

nervous system tumors in various clinical trials (clinicaltrials.gov identifiers NCT03901950, NCT02675946, and
NCT03447470) [44]. NCT03901950 is a phase 1 trial investigating study drug XNW7201, a Wnt protein blocker in
patients with advanced solid tumors. NCT02675946 is investigating study drug CGX1321, a Wnt pathway inhibitor
in patients with advanced solid tumors and in combination
with Pembrolizumab in patients with advanced gastrointestinal tumors. Finally, NCT03447470 is a phase 1 trial
investigating Wnt inhibitor RXC004 as monotherapy or in
combination with Nivolumab in patients with advanced malignancies. Despite its promising potential, it is vital to note
that β-catenin/Wnt targeting is possibly associated with significant off-target effects [44].

aCPs also show upregulation of SHH signaling (GLI2,
PTCH1, and SHH) pathways in comparison with pCPs. The
SHH signaling pathway, essential to organ development
and maintenance of stem cell niches, is also upregulated
in both mouse and human aCPs [24]. SHH binds to the
receptor Patched 1 (PTCH1), resulting in disinhibition of
Smoothened (SMO), a transducer. Once active, SMO induces a signaling cascade and activates target genes. In
gene expression studies of aCP mouse models, SHH was
overexpressed in β-catenin cell clusters. In humans, expression of SHH mRNA and receptor PTCH1 have also
been found in β-catenin cell clusters. Therefore, SMO inhibitors are another potential therapy in CP management
and have demonstrated success in treating advanced human
cancer [45].

5

7. Epidermal Growth Factor Receptor
Signaling in CP
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that has also been found to be overexpressed in both human and mouse aCPs [32]. Similarly to
β-catenin, EGFR activation is associated with cellular proliferation, differentiation, motility, and apoptosis. In cell
clusters of aCPs, EGFR has demonstrated high rates of expression. In vitro and animal studies have demonstrated
the correlation of EGFR pathway activation with enhanced
fascin-1 expression, cell growth, and migration in aCP cells
[46–48]. Fascin is a cytoskeletal actin-binding protein that
manages cell motility and invasiveness [49]. Furthermore,
the presence of an activated EGFR pathway in β-catenin–
accumulating cells at the infiltrating borders of the tumor
supports the role of EGFR in brain invasion [46,50–52].
Stache et al. [53] demonstrated the impact of EGFR signaling on promoting aCP resistance to radiation through
enhancing survivin (an antiapoptotic protein) gene expression. They have also reported that inhibition of EGFR activity leads to increasing cell death in response to radiotherapy
[53].

8. Other Signaling Pathways
Different cell populations are implicated in the pathogenesis of aCPs. Cell clusters, characterized by whorllike patterns near the infiltrative regions of the tumor, have
an unknown function but represent a different cell population from other tumor cells [3]. Cell clusters in aCPs have
demonstrated differential increased expression of Axin2
and BMP4 RNA as well as increased protein translation
in comparison with surrounding tumor cells. In addition,
increased cellular migratory potential is seen, indicating
that other mechanisms determine which cells form clusters
[24,46].
Sox2+ stem cells represent another distinct population of cells that have been shown to stimulate tumorigenesis via a paracrine mechanism [3]. Embryonic induced
mice expressing degradation-resistant β-catenin in Sox2+
cells have been shown to develop tumors with β-catenin–
accumulating cluster cells similar to those of human aCPs
[54]. Interestingly, genetic tracing and molecular analyses have shown that pituitary tumors do not originate from
Sox2+ stem cells, but the stem cell clusters do release factors that impact the surrounding tissue and may induce cell
transformation and tumor growth [24,55]. It is proposed
that Sox2+ cells form quiescent β-catenin–accumulating
clusters of daughter cells that are secretory and quiescent
and signal via members of fibroblast growth factor (FGF),
transforming growth factor beta (TGF-β), epithelial growth
factor, SHH pathways, cytokines, and chemokines [3].

6

9. aCP Cystic Tumor Pathogenesis
The cystic component of CP is responsible for significant symptoms due to mass effect and is associated with a
risk of recurrence [56]. Management of cystic CPs may involve intracavitary delivery of radioisotopes or drugs which
allows for local treatment to the cyst lining leading to elimination of the secretory epithelial lining and ultimately deficient fluid production and cyst shrinkage [7]. Nonetheless,
targeted therapies targeting the cystic component of CPs
represent an intriguing potential option for treatment. Several agents have been studied in cystic areas of CP, including P32, interferon (IFN), and bleomycin [57,58]. However, improved understanding of the cystic components of
CP has opened the possibility of more targeted treatment
options.
Human aCPs are characterized by a combination of
both solid and cystic components within the tumor, and
molecular studies have characterized important inflammatory mediators in the solid and cystic components. Cystic fluid in human aCPs has been found to contain elevated
levels of cytokines and chemokines, specifically interleukin
(IL)-6, IL-8, IL-10, CXCL1, indoleamine 2, 3-dioxygenase
(IDO)-1, and defensin 1-3 [59,60]. Similarly, in solid components, transcript levels of IL-6, CXCL, IL-6, and CXCR2
were elevated. In vitro studies have identified the role of
IL-6 in mitogenesis, growth, and migration of aCP cells
[30,60]. aCPs were also found to have higher transcript levels of immunosuppressive factors IL-10 and IDO-1. These
findings are relevant given that they represent the role of immune system modulators in tumor behavior. For instance,
IL-6 is an important activator of the STAT3 pathway, which
leads to chronic inflammation and suppression of antitumor activity when dysregulated [61]. Similarly, IL-10 has
been observed to have an immunosuppressive role in the
brain and in tumor models [62,63]. Alpha defensins 1–3
and antimicrobial peptides involved in the innate immune
system have been identified in the cystic component of CPs
[59]. Importantly, alpha defensin expression decreases after treatment of CPs with IFN-α and correlates with the effectiveness of this treatment, highlighting the role of immune mediators in tumorigenesis. The entire role of immune system modulators in aCP tumorigenesis has yet to
be described, but these findings point to the potential role
of targeted therapy toward immune system modulators. To
our knowledge, no studies have investigated the cystic and
solid components of pCPs.

10. Molecular and Immune Mediators of CP
Recurrence and Tumor Growth
Recurrence of CPs represents a formidable challenge
because of the unpredictable behavior, morbidity, and potential mortality. CPs have a recurrence rate of approximately 65%, with most occurring within the first 10 years
after surgery [64]. Given that the histologic subtype is not
likely to provide prognostic value, other molecular markers

may have higher relevance. In terms of histologic features,
the presence of cystic lesions or whorl-like arrays in aCPs
has been associated with higher risks of recurrence [25].
Reactive gliosis, a response consisting of proliferation and
hypertrophy of glial cells after damage, has also been associated with increased rates of recurrence, although only one
study has provided supportive evidence [25].
Molecular markers can be significant predictors of CP
recurrence. According to Coury et al. [25], molecular
markers that have consistently yielded convincing evidence
regarding expression and increased risk of recurrence include Ki-67, epithelial cell adhesion molecule (Ep-CAM),
pituitary tumor transforming gene (PTTG-1), survivin, specific retinoic acid receptor (RAR) subtypes, osteonectin,
and the chemokines CXCL12 and CXCR4. Increased expression of Ki-67, a marker of proliferation in tumors, has
been found in aggressive CPs and predicts a higher risk
of recurrence and faster tumor growth. Similarly, the antiapoptotic protein survivin is upregulated in the brains of
CP patients compared with healthy brains [65]. Interestingly, survivin had higher expression in aCPs compared
with pCPs or recurrent tumors. Furthermore, EpCAM, a
cell adhesion molecule associated with several cancers, and
PTTG-1, an oncogene, show increased expression in recurrent aCPs compared with primary CPs [66]. The presence
of osteonectin, a glycoprotein with a role in tumor angiogenesis and proliferation, in the stroma surrounding the CP
has also shown a positive correlation with CP recurrence
rate [67]. The expression and lack of expression of certain retinoic acid receptor (RAR) subtypes is also associated with recurrence. RARs have a role in cell maturation and differentiation. Low RAR-B and high RAR-y expression in CPs was associated with a higher risk of recurrence within two years of surgery [68]. Finally, expression
of chemokines CXCL12/CXCR4 has been associated with
worse progression-free survival in pediatric CPs [69].
Moreover, recurrent tumors are characterized by upregulation of angiogenesis, as driven by vascular endothelial growth factor (VEGF). Indeed, recurrent CPs have
higher expression of VEGF, and aCPs have been shown
to have higher VEGF expression in comparison with pCPs
[70,71]. The latter finding supports previous descriptions of
aCP as more invasive and difficult to resect. More recently,
molecular profiling has revealed the presence of senescent
cells in mouse and human aCPs [72]. Senescent cells secrete senescence associated secretory phenotype (SASP),
proinflammatory cytokines, chemokines, growth factors,
and proteases. SASP is responsible for the recruitment of
immune cells for elimination and promotes the progression
of tumor cells via promotion of angiogenesis, extracellular
matrix remodeling, or epithelial mesenchymal transition. In
fact, it has been shown that targeting the SASP response in
β-catenin cluster cells leads to a reduction in tumor inducing potential and highlights a need for further investigation
into the role of senescent cells in aCPs.

Immune checkpoint inhibitors have been used and approved for treatment of a variety of cancers, and their role in
CP management remains to be explored. pCPs have shown
expression of programmed-death ligand 1 (PD-L1) in some
tumor cells [73], and Lin et al. [74] reported that recurrent CPs have more PD-L1–expressing cells than primary
CPs. Another study of PD-L1 expression showed that it
was predominant in the cyst lining of aCP and colocalized
with β-catenin in the nucleus [73]. In comparison, PD-L1
was primarily within the tumor stromal fibrovascular cores
in pCP. These studies indicated that immune checkpoint inhibitors may have a role in management of CPs.

11. Usage of BRAF inhibitors for pCP
Various cancers with positive BRAF mutations have
been treated with BRAF inhibitors, including melanomas
and thyroid and colorectal cancers [75–77]. The identification of BRAFV 600E mutations in pCP has unleashed a
new perspective on the pharmacological treatment of CP
[29,31–39]. A total of 11 reported cases of pCP have been
treated with a BRAF inhibitor, either dabrafenib or vemurafenib, and with or without a mitogen-activated protein kinase (MEK) inhibitor, trametinib (Table 2, Fig. 3). MEK
inhibitors could be effective by blocking the downstream
MAPK/ERK pathway, which has been shown to be downstream of EGFR signaling in CP [78,79]. The combination
of a MEK inhibitor with BRAF inhibitor in the treatment
of melanomas has been shown to reduce development of
tumor resistance to BRAF inhibitors and improves patient
survival [76,80,81].
Single-agent therapy with the BRAF inhibitor
dabrafenib (150 mg by mouth twice daily) or vemurafenib
(960 mg by mouth twice daily) was used in 4 cases
[32,34,36,40]. Dual targeted therapy using trametinib (2
mg by mouth daily), in combination with BRAF inhibitor,
was prescribed in 7 patients [29,31,33,35,37–39]. Regardless of treatment regimen, all case reports demonstrated
favorable clinical response. Tumor volume reduction—
ranging from 55% to 100%—was seen in all cases, and
both solid and cystic portions of tumor were responsive
to treatment. These reports mostly included patients
with progressive or recurrent pCP that had failed primary
treatment. The interruption of treatment because of side
effects resulted in tumor regrowth in 2 cases; however,
the tumors shrank again after readministration of agents in
both cases [29,32–40]. In another case, Himes et al. [34]
reported stable disease over 1 year after discontinuation of
dabrafenib therapy.
Combined BRAF and MEK inhibitors have been well
tolerated in all reported patients. One patient with recurrent BRAFV 600E -mutated tumor treated with dabrafenib
and trametinib had reduced tumor volume within a month of
treatment [31]. The most common adverse effect for combined inhibitors has been fever (Table 2, Ref. [29,31–40].
Other side effects include rash, arthralgia, myalgia, cough,
7

Fig. 3. Signaling pathway and targeting of papillary craniopharyngioma. Constitutive activation of the BRAF signaling pathway
occurs with the V600E mutation in papillary craniopharyngioma. Inhibition of BRAFV 600E with vemurafenib or dabrafenib along with
inhibition of MEK with tramatinib has shown efficacy. ERK, extracellular signal-related kinase; MEK, Mitogen-activated protein kinase
kinase; RTK, receptor tyrosine kinase; RAS-GTP, Ras-guanosine triphosphate.

and elevated liver enzymes. These symptoms also have
been reported in patients treated with BRAF inhibitor for
other type of diseases [82–84].
Preoperative treatment with BRAF/MEK inhibitors
may be helpful as a neoadjuvant treatment by reducing tumor volume. Juratli et al. [37] reported a patient with
BRAFV 600E -mutated pCP who received dual-agent targeted therapy after biopsy of lesion. A significant reduction in the tumor size (>80%) and improvement of the patient’s symptoms was observed after 6 months of treatment
[37]. This report for the first time suggested the potential
use of targeted therapy as a neoadjuvant treatment. Further
investigations, particularly clinical trials, are needed to determine the optimal drug combination, dose, and duration,
as well as to evaluate the safety and efficacy of treatment.
Recently, minimally invasive and noninvasive methods for preoperative tumor diagnosis including the use
of magnetic resonance imaging characteristics that predict
BRAF-mutated pCP [41,85] and detection of circulating
BRAFV 600E mutations in peripheral blood have been described [31]. These proposed diagnostic approaches need
to be validated in prospective studies; however, if a BRAF8

mutated pCP could be identified preoperatively through
reliable noninvasive techniques or a routine tissue biopsy
(using image-guided transcranial or transsphenoidal techniques), neoadjuvant targeted therapy with these agents
could reduce tumor burden and facilitate surgical intervention or radiation therapy and potentially reduce associated
morbidities.

12. Potential Use of EGFR Inhibitors
EGFR inhibitors, as either monoclonal antibodies or
tyrosine kinase inhibitors, represent a potential therapeutic in the management of CPs and have been efficacious
for the treatment of non–small-cell lung cancer (NSLC),
breast, and colorectal cancer [86]. Indeed, in vitro experiments have demonstrated that gefitinib (a selective EGFR
inhibitor) treatment prevents migration and motility of tumor cells and significantly reduces fascin mRNA expression in aCP cells [78]. In addition, EGFR inhibitors could
provide another therapeutic benefit by increasing tumor cell
sensitivity to radiation [53]. Further animal models and preclinical studies will be needed to investigate the benefit of
EGFR inhibitors in the treatment of aCPs.

Table 2. Studies describing the use of targeted therapy in BRAFV 600 -mutated papillary craniopharyngiomas.
Paper

Age/Sex

Prior treatment

Targeted treatment agent(s)

Duration

Treatment after
targeted therapy

Response to treatment

Final outcome

Complication(s)

39/M

5 surgeries

dabrafenib 150 mg bid + trametinib 2
mg bid (after 21 days)

52 days

TSS + RT

85% and 81% reduction
in solid and cystic
components at 35 days

stable disease
after 18 mo

Low-grade fever

Aylwin et al. 2016 [32]

57/F (27 at
diagnosis)

3 surgeries + RT

vemurafenib 960 mg bid

10 mo (3 mo
interruption
after 3 mo)

Progression
after 7 mo

CSF leak with
meningitis due to tumor
shrinkage

Rostami et al. 2017 [29]

65/M

1 surgery

dabrafenib 150 mg bid + trametinib 2
mg daily (after 21 days)

7 weeks

RT

91% reduction of the
tumor at 15 weeks

fever

Roque et al. 2017 [33]

47/F

1 surgery + Ommaya
cyst aspiration + RT

dabrafenib 150 mg bid + trametinib 2
mg daily

7 mo

none

near disappearance of
tumor at 7 mo

intermittent fever

Himes et al. 2018 [34]

52/M (47 at
diagnosis)

1 surgery + RT

dabrafenib 150 mg bid (dose
reduction after several weeks then
dose was increased to 225 mg daily)

12 mo

none

significant decrease in
tumor size at 6 mo

Bernstein et al. 2019 [35]

60/M

4 surgeries + RT

dabrafenib 150 mg bid + trametinib 2
mg daily (after 14 days)

28 mo

none

Rao et al. 2019 [36]

35/M

1 surgery + shunt

dabrafenib 150 mg bid

24 mo

none

Complete response of
solid component at 24
mo

none

Juratli et al. 2019 [37]

21/M

biopsy

dabrafenib 150 mg bid + trametinib 2
mg daily

6 mo

none

80% response at 6 mo

none

Khaddour et al. 2020 [38]

39/M

1 surgery

dabrafenib 150 mg bid + trametinib 2
mg daily

9 mo

gamma knife
radiosurgery

Brastianos et al. 2016 [31]

Di Stefano et al. 2020 [39]
Chik et al. 2021 [40]

55/F

1 surgery

dabrafenib 150 mg bid + trametinib 2
mg daily

12 mo

37/M (10 at
diagnosis)

4 surgeries

vemurafenib 960 mg bid

40 mo

RT, radiotherapy; bid, twice daily; TSS, transsphenoidal surgery; CSF, cerebrospinal fluid.

surgery for CSF leak near-complete resolution
after 3 mo

RT

stable disease 1
year off therapy

100% tumor reduction at
complete
2 mo
response at 28
mo

>70% tumor reduction in remission for

at 9 mo

2 years

94.5% tumor shrinkage
after 72 days

stable at 385
days

2 surgeries followed 55% tumor reduction at
by RT and gamma
15 mo
knife

joint pain

verrucal keratosis

mild fever
fatigue, coughing,
peripheral edema
arthralgia, myalgia,
elevated liver enzymes,
severe sun sensitivity
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13. Tyrosine Kinase Inhibitors of VEGF
Receptors
VEGF regulates angiogenesis and promotes tumor
growth, metastasis, and recurrence [86,87]. One downstream pathway in aCP of Wnt/β-catenin signaling is expression of VEGF [9,79,87]. Studies demonstrated that
recurrent aCPs show higher levels of VEGF expression
than primary tumors, suggesting that VEGF expression may
have an important role in growth and invasiveness of aCP
[88–91]. Furthermore, Hu et al. [92] showed the association of VEGF expression with CP radiosensitivity. Tumors with a higher level of VEGF receptor-2 expression are
insensitive to 32 P-colloid interstitial radiotherapy. These
findings suggest that the VEGF pathway could be a potential target in medical therapy of aCP. New treatment modalities with VEGF inhibitors, such as bevacizumab, could
have a therapeutic benefit in the management of CP. Higher
VEGF expression in recurrent and aCP tumors suggest that
tyrosine kinase inhibitors of VEGF receptor may have a
therapeutic role in preventing or delaying CP recurrence
[92]. No trials have evaluated the use of VEGF inhibitors
alone in aCP patients. Grab et al. [93] reported a significant
decrease in tumor cyst size after treatment with combination
of systemic tocilizumab (a monoclonal antibody against IL6 receptor) and bevacizumab in a case of recurrent aCP.

14. Role of Directed Therapies against
Inflammatory Mediators in aCP
The role of the immune microenvironment in CP
pathogenesis is increasingly recognized in recent years
[94], and several studies have attempted to evaluate the use
of selective inflammatory blockade as a potential therapeutic target for treatment of aCP [44]. IFN has antitumor activity through inhibition of cell proliferation and modulation of the host’s immune response [95,96]. Several studies
have investigated the efficacy of intracystic and systemic
administration of IFN with promising results. Cystic treatment can delay surgery or radiotherapy through cyst shrinkage, which can reduce the patient’s risk profile for treatment, especially in children [97–100]. Jakacki et al. [101]
reported the result of systemic IFN-α2a administration in
patients with progressive or recurrent CP. Among 12 patients at the end of study, a radiologic response was demonstrated in 3 patients with predominantly cystic tumors (one
patient with complete response). In patients without progressive disease that completed one year of therapy, progression was seen in 3 and 6 patients after discontinuation
of IFN, respectively. The median time to progression was
25 months. Yeung et al. [102] explored the efficacy of pegylated IFN in treatment of 5 patients with recurrent CP. Pegylated IFN-α2b was shown to be more effective because of
longer plasma half-life compared with non-pegylated IFN
[103]. All patients treated with pegylated IFN-α2b experienced stable disease or better in response to treatment (2
complete responses, 2 partial responses, 1 stable disease)
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[102]. No evidence of disease progression was observed
during the follow-up period. Like the previous study, all patients had predominantly cystic tumors in this series [102].
The Pediatric Brain Tumor Consortium conducted a multicenter phase 2 study of using pegylated IFN-α2b in children
and young adults with unresectable or recurrent CP [104].
Among 7 patients who did not have previous radiotherapy,
2 had a partial response and 1 had a durable response >3
months. No patient who failed radiotherapy had a response
with pegulated IFN-α2b, but treatment was well tolerated.
While promising, the role of IFN as an alternative treatment
for patients with recurrent or progressive CP remains unclear given that these studies had small sample sizes, short
follow-up periods, and did not include solid CPs. Still, the
use of IFN in the future, particularly in tumors with a predominantly cystic component warrants further investigation
given that it has been shown to delay disease progression
and may defer the need for radiation therapy in children
with CP.
Targeting of IL-6 has been evaluated as a method to
modulate inflammatory signaling in CPs. Grob et al. [93]
reported the first systemic use of tocilizumab, a monoclonal
antibody against IL6-R, in the management of two patients
with cystic aCP that was refractory to intracystic therapy.
They administered tocilizumab alone in one patient and
tocilizumab in combination with bevacizumab (VEGF inhibitor) in another. A partial tumor response and significant decrease in cyst volume were seen in both patients.
Grob et al. [93] proposed tocilizumab as a new potential
agent for the treatment of cystic aCP. Currently, a Phase 0
clinical trial (NCT03970226) is investigating the efficacy
of tocilizumab in the management of aCP.

15. Current Clinical Trials in CP
Only a handful of clinical trials are currently evaluating targeted agents in CP (Table 3). A Phase 2 clinical
trial (NCT03224767) is investigating the combined use of
BRAF and MEK inhibitors (vemurafenib and cobimetinib)
for the treatment of BRAFV 600E mutant pCPs in adults 18
years or older. Patients are given vemurafenib for 28 days
combined with cobimetinib for 21 days with up to 5 repeated cycles. Outcome measures include response rate,
progression-free survival, and overall survival.
NCT03970226 is a phase 0 study examining the role
of tocilizumab, a monoclonal IL-6 antibody, in the treatment of newly diagnosed and progressed aCPs in children
and adolescents 2 to 21 years of age. In this study, patients are given systemic tocilizumab, and the presence
of drug metabolites, IL-6 levels, and other inflammatory
markers are measured within tumor tissue, tumor cyst, or
CSF fluid. If drug metabolites are detected, patients are eligible for concurrent enrollment to evaluate the efficacy of
tocilizumab by measuring progression-free survival, overall response rate, 1-year disease stabilization, and tissue
analysis using various biomarkers. Lastly, NCT03610906

Table 3. Current clinical trials in molecular targeted therapy of CP.
Clinical trial

Phase

Molecular target

Objective

NCT03224767

II

BRAF Pathway

NCT03970226

Zero

IL-6

NCT03610906

I/II

To study the combined used of BRAF and MEK inhibitors (vemurafenib and
cobimetinib) for the treatment of BRAFV 600E mutant papillary craniopharyngiomas in
adults 18 years or older
To study the role of tocilizumab, a monoclonal IL-6 antibody, in treatment of newly
diagnosed/progressed aCp in children and adolescents ages 2–21 years
To identify new potential areas of target in pediatric patients

is a phase 1/2 study that aims to identify new potential areas of target in pediatric patients but is not examining any
targeted treatment.

16. Conclusions
There are multiple promising genetic and molecular
biomarkers being explored for prognostic and therapeutic
purposes in CP. Differences in histology, namely between
aCP and pCP, do not necessarily correlate with prognosis
and outcomes; however, different mechanisms for pathogenesis of these subtypes have aided in understanding the
disease and targeting therapeutics. Overexpressed oncogenes in CP include genes controlling cell growth, proliferation, and angiogenesis among other pathways. These mutations can serve as both therapeutic targets and biomarkers
of prognosis. Furthermore, variations in molecular markers can be seen in recurrent versus primary CP, indicating
that differences in mutational signatures could potentially
help understand and predict recurrence. Inhibition of some
genes overexpressed in recurrent CP may be able to reduce
recurrence rates overall. Currently, the primary treatment
for recurrent CPs should include repeat surgery or radiosurgery given that current investigative targeted therapies
are emerging.
Oncogenic gene mutations in CP are also implicated
in other forms of cancer and have been targeted for therapy
with molecular inhibitors. Drugs targeting these pathways
have been tested with reasonable success on medically managed CPs. Apart from pure medical treatment, a promising
application for such drugs is for neoadjuvant therapy to be
followed by radiation or resection. EGFR inhibitors could
both prevent tumor growth and sensitize the tumor to subsequent radiation therapy. Inhibitors of the BRAF/MEK
pathway in pCP have proven to be effective in shrinking
tumors and may facilitate resection. VEGF inhibitors, in
combination with IL-6 inhibitors, have also been shown to
reduce tumor size, although no studies have been done with
VEGF inhibitors alone. Further studies and clinical trials
are needed to examine these applications for their therapeutic potential. Immunotherapy may also have potential for
combating CP growth and spread. Current clinical trials are
examining the use of IL-6 inhibition in CP treatment. The
expression by pCP tumors of PD-L1, especially in recurrent
tumors, also suggests anti-PD-1/PD-L1 immunotherapy as
a potential route for CP therapy.

Challenges remain in applying our knowledge of
molecular drivers towards clinical treatment in CP. Only
a handful of clinical trials are currently evaluating the role
of molecular treatments, with reports of successful agents
only being found in rare case reports. Driver mutations and
their associated signaling pathways should be further explored within in vitro and animal models; however, clinical
studies are also required to translate the therapeutic value in
CP management and establish the efficacy of these agents.
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